KIAA1429 can promote the resistance to gefitinib, an EGFR (epidermal growth factor receptor) inhibitor, by increasing MAP3K2 (mitogen-activated protein kinase kinase kinase 2) expression in lung adenocarcinoma [29], or by suppressing autophagy mediated by WTAP in non-small cell lung cancer [30]. Here, VIRMA is linked to lung adenocarcinoma.